Airing Treatment Advances in Breast Cancer in New York

We recently traveled to Long Island, New York, for an OncLive^® State of the Science Summit™ on Breast Cancer. At the meeting, faculty from NYU Langone’s Perlmutter Cancer Center shed light on how to balance genomic and clinical risk in hormone receptor­—positive disease, novel approaches that are pushing the envelope in HER2-positive disease, and how tumor biology is being used to personalize surgical interventions. Other topics included exciting therapies that are propelling progress in the treatment of HR-positive, HER2-negative disease and how the paradigm for triple-negative disease is evolving with the emergence of antibody-drug conjugates, PARP inhibitors, and immunotherapy.